Heart Failure and Atrial Fibrillation: Unveiling Shared Genetic Roots
New research published in Nature Cardiovascular Research indicates that heart failure and atrial fibrillation share common underlying genetic and molecular mechanisms. These findings suggest the two cardiovascular conditions may be more closely related than previously understood.
Condition Overviews
- Heart failure: Occurs when the heart muscle is damaged and unable to pump sufficient blood to meet the body's oxygen needs. This condition is typically evaluated in the heart's lower chambers (ventricles), which are responsible for most of the heart's pumping action.
- Atrial fibrillation (AFib): An irregular heart rhythm (arrhythmia) originating in the heart's upper chambers (atria). AFib results in a rapid heartbeat, reduced blood flow, and an increased risk of clots or stroke.
Epidemiological observations have shown a strong association between these conditions: individuals with heart failure are more likely to develop atrial fibrillation, and vice versa. Patient outcomes tend to be less favorable when both conditions are present.
Senior author Ivan Moskowitz, MD, PhD, described this intersection as a significant issue in cardiology.
Discovery of TBX5 as a Key Regulator
Previous research by Moskowitz's team in 2024 involved creating a mouse model. They aimed to develop a heart failure model by increasing a gene linked to human heart failure, but instead observed an atrial fibrillation model. This unexpected finding led to focusing on the gene TBX5.
TBX5 functions as a transcriptional regulator, a protein that controls gene activation and deactivation in the cell nucleus. When TBX5 levels decrease in the atrium, it disrupts normal gene expression required for maintaining a stable heart rhythm.
Researchers compared different mouse models of heart failure and atrial fibrillation. They found that an atrial fibrillation model, created by removing TBX5 from the atria, produced gene expression changes nearly identical to those observed in heart failure. Analysis of human gene expression data further showed that TBX5 was significantly downregulated in the atria of heart failure patients, but not in their ventricles. This suggested a mechanistic link where reduced TBX5 in the atrium could contribute to atrial fibrillation development in the context of heart failure.
Coordinated Genetic Response
Further analysis identified over 100 other transcription factors that were altered similarly in both the heart failure and TBX5-deficient atrial fibrillation models. Most of these key transcription factors changed in the same direction across both conditions. This correlation suggests that, from the atrium's perspective, the underlying processes in both conditions are similar.
Using single-cell analysis, the team identified cardiomyocytes (heart muscle cells) and fibroblasts (connective tissue cells) in the human atrium as cell types involved in this disease mechanism. This indicates that the pathological response involves communication between multiple cell types.
Reconceptualizing Atrial Fibrillation
The study's authors propose a fundamental shift in understanding atrial fibrillation. They suggest that the rhythm disorder observed in atrial fibrillation may be a symptom of underlying atrial muscle dysfunction, comparable to the ventricular dysfunction seen in heart failure.
Moskowitz stated that atrial fibrillation could be viewed as 'atrial heart failure' or an 'atrial myopathy,' rather than solely a rhythm disorder.
Implications for Future Treatments
This new perspective may have significant implications for cardiovascular disease treatment. Current therapies for atrial fibrillation primarily focus on controlling the heart's electrical rhythm by targeting ion channels. Moskowitz suggests exploring a broader approach, potentially by addressing upstream mechanisms. This could involve considering the atrium's response to pressure in a manner similar to how ventricles are treated in heart failure.
Ongoing research at UChicago Medicine continues to analyze these genetic and molecular pathways. Researchers have identified multiple signaling genes in cardiomyocytes that are disrupted when TBX5 is reduced. Efforts are underway to investigate whether restoring these signals can prevent atrial fibrillation.